The Multidisciplinary Team (MDT) Approach: Why Complex Healthcare Demands Collective Expert Intelligence

1. What Is the Multidisciplinary Team Approach — and Why Was It Created?

When a person faces a serious, complex medical condition — a newly diagnosed cancer, a rare autoimmune disease, a multi-organ disorder, or a condition that has not responded to standard treatment — the single most important question they face is not "which doctor should I see?" It is "which team of doctors, working together, should review my case?" This distinction is the foundation of the multidisciplinary team, or MDT, approach to healthcare.

The MDT model recognizes a fundamental truth about complex medicine that took the global healthcare community decades to fully accept: no single specialist, however talented, possesses all the knowledge, perspective, and expertise required to make optimal decisions about a truly complex medical case. The human body is an interconnected system. Disease does not respect the boundaries of medical specialties. A patient with liver cancer is simultaneously a gastroenterology patient, an oncology patient, a surgical patient, a radiology patient, and a pathology patient — and the optimal treatment plan can only emerge when all those perspectives are integrated simultaneously, not sequentially.

The formal MDT model as practiced today traces its clearest origins to oncology in the 1990s and early 2000s, when growing evidence began demonstrating that cancer patients whose cases were reviewed by multidisciplinary tumor boards had significantly better outcomes than those managed by individual specialists in isolation. The United Kingdom's National Health Service (NHS) mandated MDT review for all cancer patients in 2000, and this requirement has since spread as a recognized standard of care across the European Union, North America, and leading Asian healthcare systems — including China's top-tier hospitals.

Today, the MDT approach has expanded far beyond oncology. It is now the recognized standard for managing complex cardiac conditions, rare neurological diseases, autoimmune disorders, multi-system organ failure, complex surgical planning, rare genetic conditions, and a growing range of conditions that defy straightforward single-specialty management. At MedBridge, we consider the presence of a formal, functioning MDT to be one of the most critical indicators that a hospital is genuinely equipped to manage your condition — not just willing to accept your case.

1.1 The Difference Between a Referral Network and a True MDT

One of the most important distinctions that international patients must understand before selecting a healthcare provider is the difference between a hospital that has a referral network of specialists and one that operates a genuine multidisciplinary team. These are not the same thing, and conflating them can lead to significantly suboptimal care.

A referral network is a sequential process: your primary physician refers you to a cardiologist, who may refer you to a nephrologist, who may refer you to a surgeon — each assessing you independently, each forming their own view, and each potentially making recommendations that are not fully informed by the perspectives of the other specialists involved. This approach works adequately for straightforward conditions. For complex, multi-system conditions, it introduces dangerous gaps: each specialist sees only their piece of the puzzle, coordination failures occur between referrals, and no single person or group is accountable for the holistic treatment plan.

A true MDT, by contrast, is a simultaneous, structured, collaborative review of the complete clinical picture. All relevant specialists are in the same room (or, increasingly, the same video conference) at the same time, reviewing the same imaging, the same pathology, the same lab results, and the same patient history — and collectively arriving at a unified treatment recommendation that reflects the integrated expertise of every discipline. The MDT does not recommend; it decides. And its decision is the product of professional debate, peer challenge, and the synthesis of multiple expert perspectives.

1.2 Why the MDT Model Is Now Considered Non-Negotiable for Complex Care

The evidence base for MDT-based decision-making has become sufficiently robust that leading international medical organizations now consider it not merely a best practice but a quality standard. The European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the European Association for Cardio-Thoracic Surgery (EACTS), and the World Health Organization (WHO) all incorporate MDT review as a core quality requirement in their clinical guidelines.

For patients researching overseas medical care through MedBridge, this has direct practical implications. When evaluating a hospital, one of the first questions our clinical coordinators ask is not "how many beds does this institution have?" or "what equipment do they own?" — it is "does this institution operate a formal, regularly convened MDT for the relevant condition, and can you provide documentation of how that MDT functions?" Institutions that cannot answer this question clearly are not equipped to manage genuinely complex cases.

2. The Science Behind Collective Intelligence: Why Multiple Expert Minds Consistently Outperform Single Expert Minds

The superiority of collective expert decision-making over individual expert decision-making is not a philosophical preference or an administrative convenience. It is a well-documented phenomenon supported by decades of research across multiple fields — from cognitive science and organizational behavior to clinical medicine and surgical outcomes. Understanding why groups of experts consistently outperform individuals in complex decision tasks helps explain why the MDT model produces measurably better patient outcomes.

The foundational concept is known as collective intelligence — the capacity of a group to solve problems and make decisions that exceed the capability of any individual member of that group. Research pioneered by Thomas Malone at MIT's Center for Collective Intelligence has demonstrated that groups consistently outperform their best individual members on complex, uncertain tasks precisely because the group benefits from the diversity of knowledge, perspective, and analytical approach that its members bring. In medicine, this translates directly: the oncologist sees what the radiologist may have missed; the pathologist's molecular findings change the surgeon's operative plan; the palliative care specialist identifies patient priorities that reshape the entire treatment strategy.

Critically, the benefits of collective intelligence in medicine are not merely additive — they are transformative. The synthesis that emerges from genuine MDT deliberation is qualitatively different from what any individual specialist would have recommended in isolation, not just incrementally better. Published data from major cancer centers in the United States, United Kingdom, and — increasingly — China consistently show that MDT review changes treatment recommendations in 20–40% of cases, and that these changes are associated with improved outcomes across measures including response rate, progression-free survival, and overall survival.

2.1 How Cognitive Diversity Prevents Diagnostic Error in Complex Cases

Complex medical cases are particularly vulnerable to a cognitive phenomenon known as premature closure — the tendency for an expert, once they have formed a diagnostic hypothesis, to stop actively seeking evidence that might contradict it. Premature closure is one of the most significant contributors to diagnostic error in medicine, and it disproportionately affects individual expert decision-makers rather than teams.

The MDT structure systematically reduces premature closure through several mechanisms. When a radiologist presents imaging findings to a tumor board that includes a pathologist, a surgeon, and a medical oncologist, each of those specialists is likely to notice different features of the same images, ask different questions, and bring different hypotheses to the table. The radiologist's initial interpretation is challenged, refined, or validated by perspectives that the radiologist's own training does not provide. This iterative, multi-perspective interrogation of evidence is what makes MDT diagnosis more accurate than individual diagnosis for complex cases.

• Error detection: MDT review has been shown to identify diagnostic errors missed by individual specialists in approximately 12–18% of complex cancer cases reviewed.
• Treatment optimization: In cardiac care, the heart team model — a specific MDT format for structural heart disease — has been shown to improve appropriate patient selection for complex procedures, reducing both under-treatment and over-treatment.
• Guideline adherence: Patients whose cases are managed through formal MDT processes are significantly more likely to receive treatment consistent with evidence-based clinical guidelines than those managed through individual referral pathways.
• Patient safety: MDT review provides an additional layer of safety oversight, catching contraindications, drug interactions, and procedural risks that single-specialty assessment may overlook in complex patients with multiple concurrent conditions.
• Research integration: MDT teams at academic medical centers — including China's leading tertiary hospitals — systematically integrate new research findings into clinical decision-making at a pace that individual practitioners working in isolation cannot match.

2.2 The Communication Advantage: Why Shared Records and Real-Time Discussion Matter

Beyond the intellectual benefits of collective expert deliberation, the MDT model provides a second, equally important advantage: seamless communication and shared information infrastructure. In a true MDT, every participating clinician has access to the same comprehensive clinical record, the same imaging, the same pathology report, and the same patient history simultaneously. There is no degradation of information as it passes from one specialist to another through referral letters and verbal handoffs. The treatment plan that emerges from the MDT is immediately communicated to every member of the team simultaneously, eliminating the coordination failures that plague sequential referral systems.

For international patients receiving care abroad — particularly in China's top tertiary hospitals — this communication infrastructure has additional significance. When a patient's case is reviewed by an MDT at a Grade 3 Class A hospital, the unified treatment recommendation they receive is documented in a single comprehensive report that covers every dimension of their care: the diagnostic conclusion, the proposed treatment approach, the anticipated milestones, the monitoring plan, and the contingency protocols if initial treatment is not effective. MedBridge then ensures that this comprehensive documentation is translated into English and communicated clearly to the patient and to their home-country healthcare team, maintaining the information integrity that the MDT process creates.

2.2.1 Digital MDT Platforms and AI-Assisted Decision Support: The Emerging Frontier

China's leading tertiary hospitals are at the forefront of integrating digital tools and artificial intelligence into the MDT process. Several Grade 3 Class A institutions — including West China Hospital, Peking Union Medical College Hospital, and Zhongshan Hospital — have implemented AI-assisted diagnostic support systems that analyze imaging data, pathology slides, and genomic sequencing results before MDT meetings, providing the human expert team with AI-generated differential diagnoses, risk assessments, and treatment response predictions to consider alongside their own clinical judgment. These systems do not replace human MDT expertise — they augment it, providing the team with computational perspectives that complement human pattern recognition. The integration of AI-assisted tools with genuine human MDT expertise represents the current frontier of complex medical decision-making globally, and China's top hospitals are competing directly with the world's leading academic medical centers in this space.

3. Who Sits at the MDT Table? Understanding the Roles and Contributions of Each Specialist

The composition of an MDT varies depending on the condition being managed — a cancer MDT includes different specialists than a cardiac MDT, which differs again from a rare disease MDT. However, there are consistent structural patterns that define how well-functioning MDTs are composed, and understanding these patterns helps patients assess whether the team reviewing their case has the breadth of expertise genuinely required.

The most important principle is that an MDT should include every specialist whose expertise is directly relevant to the decision being made — not merely those who are convenient or routinely available. A liver cancer MDT that does not include an interventional radiologist is making decisions without knowledge of the full range of available interventional options. A complex cardiac MDT that does not include a heart failure specialist may optimize for procedural success at the expense of long-term cardiac function management. Patients and their advocates should not hesitate to ask whether an MDT's composition truly reflects the full scope of their condition's management requirements.

3.1 Core MDT Members: The Specialists Who Are Always Present

3.2 Extended MDT Members: Condition-Specific Expertise That Changes Outcomes

Beyond the core team, effective MDTs draw on a broader range of expertise based on the specific complexities of each case. The ability to flexibly incorporate extended members is a hallmark of a well-resourced MDT operating within a major tertiary institution — and is one of the capabilities that smaller facilities and boutique clinics simply cannot replicate.

• Radiation oncologist: Essential for any MDT considering radiotherapy — whether as primary treatment, adjuvant therapy, or palliative symptom management. Radiation planning has become technically complex enough to require dedicated specialist expertise that should not be retrofitted into a treatment plan designed without it.
• Interventional radiologist or cardiologist: Provides expertise in minimally invasive image-guided procedures — embolization, ablation, percutaneous coronary intervention, TACE — that represent critical alternative or complementary options to surgery or systemic therapy.
• Geneticist / genetic counselor: Increasingly essential for MDTs managing cancers with suspected hereditary components, rare genetic diseases, and conditions where germline testing may inform not only the patient's treatment but also their family members' risk assessment.
• Palliative care specialist: Contrary to the common misconception, palliative care specialists are not present only in end-of-life situations. Early palliative care integration in complex cancer management has been shown to improve both quality of life and survival outcomes by optimizing symptom control and reducing treatment-related complications that impede therapeutic delivery.
• Pharmacist (clinical oncology or specialist pharmacy): Provides expertise on drug interactions, dosing modifications for organ dysfunction, and access to novel agents — particularly relevant for patients on complex multi-drug regimens or being considered for clinical trial protocols.

3.2.1 Patient Participation in the MDT: An Evolving Standard

One of the most significant recent developments in MDT practice internationally is the growing recognition that the patient themselves should have a meaningful voice in the MDT process, even if they do not physically attend the meeting. This manifests through several mechanisms: the clinical nurse specialist or patient advocate presenting patient-reported priorities and concerns at the MDT; the MDT explicitly addressing quality-of-life considerations alongside clinical outcomes; and post-MDT consultation processes that present the team's recommendations to the patient in a way that genuinely invites discussion, clarification, and shared decision-making. At MedBridge, we specifically ensure that our partner hospitals provide MDT recommendations in a format that supports this patient-centred approach — in English, with clear explanation of the rationale and the alternatives considered.

4. When Is an MDT Not Just Helpful but Absolutely Essential? Identifying the Clinical Situations That Require Collective Expert Intelligence

Not every medical situation requires a formal MDT. Straightforward, well-defined conditions with established, unambiguous treatment pathways can be effectively managed by appropriately trained individual specialists. The MDT model is specifically designed for — and delivers its greatest value in — situations characterized by clinical complexity, diagnostic uncertainty, multiple viable treatment options with different risk-benefit profiles, or the involvement of multiple organ systems.

Understanding when your situation falls into MDT-required territory is one of the most important pieces of healthcare literacy that an international patient can develop. It directly informs which type of facility you should seek out, and what questions you should ask before committing to a provider or treatment plan.

4.1 The Hidden Cost of Bypassing the MDT: Real-World Clinical Consequences

One of the patterns that MedBridge most frequently encounters when international patients first contact us is a history of having received care at a facility — whether in their home country or abroad — that was not equipped to provide genuine MDT review. The consequences are consistent and well-documented in the clinical literature.

Patients who receive complex cancer treatment at facilities without formal tumor board review are more likely to receive treatment that is either inappropriately aggressive (exposing them to toxicity and complications without commensurate benefit) or inappropriately conservative (missing opportunities for potentially curative intervention because a surgeon who could have offered resection was not involved in the initial treatment decision). Both forms of suboptimal treatment are associated with worse outcomes — and both are significantly more common in facilities that manage complex cases without a true MDT process.

For cardiac patients, the consequences of bypassing the heart team model can be particularly stark. Patients who receive coronary revascularization recommendations from interventional cardiologists alone — without cardiac surgical input — may be offered percutaneous intervention (stenting) when surgery would produce better long-term outcomes, simply because the interventional cardiologist's training and institutional incentives favor the percutaneous approach. The heart team model, which combines interventional cardiology and cardiac surgery expertise in a structured MDT, has been demonstrated to produce more appropriate revascularization decisions and better long-term clinical outcomes specifically because it eliminates this single-specialty bias.

4.2 Second Opinions Through MDT Review: A Specific and Powerful Use Case

For international patients who have already received a diagnosis and treatment recommendation at a facility in their home country, MDT-based second opinion review at a top-tier institution in China represents one of the most cost-effective and clinically valuable services available through MedBridge. A formal MDT second opinion — involving simultaneous review of all clinical materials by a team of relevant subspecialists — is qualitatively different from a second opinion consultation with a single specialist.

When a patient brings their pathology slides, imaging studies, and medical records to a tumor board at West China Hospital's cancer center or Fudan University's cancer hospital, those materials are reviewed not by one alternative expert but by an entire multidisciplinary team whose collective expertise spans every dimension of the patient's condition. The probability of identifying a management approach that differs meaningfully from the original recommendation — and that is superior — is substantially higher from an MDT review than from an individual second opinion consultation. And at Chinese tertiary hospitals via MedBridge, the cost of this comprehensive MDT review is typically $1,000–$3,000 — compared to $5,000–$15,000 for equivalent MDT-level second opinion processes at US academic medical centers.

5. MDT in Oncology: Understanding the Tumor Board as the Global Gold Standard for Cancer Care Decision-Making

Cancer care is where the MDT model has its deepest roots, its strongest evidence base, and its clearest international consensus. The oncology tumor board — a formal, regularly convened meeting of all specialists involved in cancer diagnosis and treatment — is now explicitly mandated by national cancer care guidelines in the United Kingdom, European Union, Australia, and is strongly recommended by leading oncology organizations in the United States. Understanding how tumor boards function, what they accomplish, and what their absence means for cancer patients is foundational knowledge for anyone facing a cancer diagnosis who is considering overseas treatment options.

A well-functioning oncology MDT typically meets weekly or biweekly. For each new case presented, the following sequence occurs: the referring oncologist presents the patient's clinical history, symptoms, and relevant risk factors; the radiologist reviews all imaging and provides a formal interpretation; the pathologist presents biopsy or surgical specimen findings, including molecular and genomic analysis; and the entire team — including surgeons, radiation oncologists, palliative care specialists, and clinical nurse specialists — collectively discusses the diagnostic conclusions, the staging assessment, and the treatment options. The MDT then reaches a consensus recommendation that is documented in the patient's record and communicated to the patient through the coordinating clinician.

5.1 How Tumor Board Review Specifically Changes Cancer Treatment Decisions

The clinical literature documenting tumor board-driven treatment changes is extensive and consistent across multiple cancer types and healthcare systems. Key findings include:

• Breast cancer: Tumor board review changes treatment recommendations in approximately 30% of cases, primarily through the identification of surgical options not initially considered, the incorporation of molecular pathology findings that indicate different systemic therapy choices, and the optimization of reconstruction timing and technique.
• Lung cancer: MDT review is particularly impactful in lung cancer staging, where the integration of PET-CT, endobronchial ultrasound findings, and molecular profiling routinely produces significantly different staging conclusions — and therefore different treatment plans — than any single modality reviewed in isolation.
• Hepatobiliary cancers: In liver and bile duct cancers, the involvement of hepatobiliary surgeons, transplant surgeons, and interventional radiologists in tumor board review routinely reveals resectability or transplant eligibility that would not be apparent from medical oncology assessment alone. These conditions have some of the highest rates of tumor board-driven treatment plan modification.
• Rare tumors: For unusual or rare cancer types, tumor board review at high-volume centers frequently leads to revised diagnoses (particularly regarding the specific tumor subtype) that fundamentally change the treatment approach. Rare tumors are precisely where the breadth of tumor board expertise is most valuable — individual specialists may encounter these cases only once or twice in their careers, while a tumor board at a major cancer center reviews them regularly.
• Clinical trial access: Tumor boards at research-active tertiary hospitals systematically evaluate every patient's eligibility for relevant clinical trials. This systematic evaluation — which cannot occur in single-specialist management — is one of the most direct mechanisms by which MDT care expands patients' access to potentially superior treatment options.

5.2 What to Ask When Evaluating a Hospital's Oncology MDT

Not all institutions that claim to have a tumor board actually operate one that meets the standards described above. Marketing language around "comprehensive cancer care" and "multidisciplinary teams" is widespread — but the substance behind that language varies enormously. When evaluating any hospital for cancer care, internationally or domestically, patients should ask specific, verifiable questions:

• How frequently does the tumor board meet, and what is the average time from referral to tumor board presentation for a new case?
• Which specific specialties are represented at every meeting, versus which are called in selectively?
• Is molecular pathology (genomic profiling, NGS) systematically integrated into tumor board presentations, or is it ordered only in selected cases?
• Are clinical trial options systematically reviewed for every patient, or only when the oncologist specifically requests it?
• Is a patient advocate or clinical nurse specialist present at every meeting to ensure patient-centered priorities are reflected?
• Is the tumor board recommendation documented in a formal report that is communicated to the patient in language they can understand?

MedBridge asks and verifies all of these questions during our institutional assessment process. Every cancer center accessible through MedBridge's partner network has been confirmed to meet rigorous tumor board operational standards — and we document this verification for patients who request it.

5.2.1 Liquid Biopsy and Real-Time Genomics: The Next Frontier of MDT-Integrated Oncology

The integration of liquid biopsy — the analysis of circulating tumor DNA from a simple blood draw — into routine MDT practice represents one of the most exciting and rapidly evolving developments in oncology. Liquid biopsy allows tumor boards to monitor treatment response, detect emerging resistance mutations, and identify new targetable alterations in real time, without requiring repeat tissue biopsies. China's leading cancer centers, including those at Sun Yat-sen University Cancer Center, Fudan University Cancer Hospital, and the Cancer Hospital of the Chinese Academy of Medical Sciences, have been early adopters of liquid biopsy integration into their tumor board processes — and currently offer this technology at a fraction of the cost charged by equivalent US institutions.

6. How China's Top-Tier Hospitals Lead Global MDT Practice — and Why This Matters for International Patients

For North American and European patients considering overseas medical care, the question of whether Chinese hospitals truly operate world-class MDT processes is critically important — and the answer, for China's top Grade 3 Class A institutions, is an unambiguous yes. Understanding the evidence for this claim, and understanding why it matters for your specific situation, is the core purpose of this section.

China's formal adoption of the MDT model as a national quality standard for complex medical care began in earnest in the mid-2000s, accelerated significantly with the National Health Commission's 2018 MDT promotion policy, and has now reached a level of institutionalization at leading hospitals that is directly comparable to — and in some dimensions exceeds — what is practiced at leading academic medical centers in the United States and Europe.

6.1 The Scale and Volume Advantage of China's Tertiary Cancer Centers

One of the most important and least understood advantages that China's top cancer centers bring to tumor board practice is sheer case volume. Clinical expertise in complex and rare conditions is inseparable from the volume of cases reviewed. A surgeon who has operated on 50 liver cancer resections in their career makes different — and statistically less accurate — judgments than a surgeon who performs 200 such resections per year. A tumor board that reviews 10 pancreatic cancer cases per month develops pattern recognition and collective expertise that a board reviewing 2 per month simply cannot replicate.

China's population of 1.4 billion produces a disease burden — particularly for cancers — that concentrates enormous case volumes at the country's leading tertiary hospitals. West China Hospital processes more than 100,000 cancer patients annually. The Cancer Hospital of the Chinese Academy of Medical Sciences — one of the world's largest dedicated cancer hospitals — reviews thousands of tumor board cases each year. For cancer types that are particularly prevalent in East Asian populations — including gastric cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, and certain subtypes of lung cancer — Chinese tumor boards have seen more cases, published more research, and developed deeper collective expertise than virtually any institution in the world.

6.2 China's MDT Research Contribution: Why International Peer Review Validates Quality

The quality of China's MDT practice is not a matter of self-assertion. It is validated by a consistent and growing body of peer-reviewed clinical research published in leading international medical journals. Chinese oncologists, surgeons, and specialists at the country's top institutions are among the most prolific publishers in their fields globally, and their research is increasingly cited by international guidelines committees.

West China Hospital's surgical MDT for esophageal cancer — a cancer type where China has the world's highest incidence — has published landmark outcome data in the Journal of Thoracic and Cardiovascular Surgery. Sun Yat-sen University Cancer Center's nasopharyngeal carcinoma tumor board has produced research that has globally redefined the staging system and treatment protocols for this disease. The hepatobiliary MDT at Zhongshan Hospital has published extensively on liver transplant selection criteria and outcomes that are now referenced in European transplant guidelines. This level of international research contribution is not consistent with institutions operating substandard MDT processes — it is the product of genuine clinical excellence.

7. Accessing World-Class MDT Care Overseas: Practical Considerations for North American and European Patients

Understanding that China's top hospitals operate world-class MDTs, and actually accessing that expertise as a patient traveling from North America or Europe, are two different challenges. The second challenge is where most patients without professional navigation support encounter significant difficulties — and where MedBridge's specific expertise adds measurable value.

The practical barriers that international patients face when attempting to access China's top-tier MDT services independently are real and should not be minimized. They include language barriers that affect not just communication but the accurate translation of medical records, imaging reports, and treatment recommendations; institutional registration processes designed for domestic patients that have no English-language interface; payment systems unfamiliar to international patients; and the absence of any established framework for coordinating the post-MDT care plan with the patient's home-country healthcare team.

7.1 The Medical Record Preparation Challenge: Why This Step Determines MDT Quality

The quality of an MDT review is only as good as the quality and completeness of the information presented to it. For international patients, ensuring that an MDT has access to all relevant clinical information — in a format that the team can effectively use — requires careful preparation that is significantly more complex than simply bringing a folder of documents to the hospital.

Digital imaging files must be provided in the correct format (typically DICOM) rather than printed films, which cannot be digitally manipulated for detailed review. Pathology slides — where the original tissue is irreplaceable — may need to be physically shipped to the Chinese center for independent review by their pathology team, as photographic images are often insufficient for the detailed molecular analysis that state-of-the-art tumor boards require. Medical records must be accurately translated by translators with specific medical training — general language translation is not adequate for clinical documentation.

MedBridge's clinical coordination team manages every element of this preparation process. We maintain relationships with certified medical translation services, DICOM-compliant imaging transfer protocols, and established pathology slide shipping procedures with China's major cancer centers. For patients whose cases we coordinate, the MDT receives a complete, accurate, and professionally prepared clinical package — maximizing the quality of the review they can provide.

7.2 The Cost Equation: What MDT-Level Care at Chinese Tertiary Hospitals Actually Costs

8. How MedBridge Connects International Patients to World-Class MDT Teams in China — Step by Step

MedBridge was specifically designed to bridge the gap between the clinical quality available at China's top-tier tertiary hospitals and the practical accessibility of that quality for international patients. Our process is not a generic medical tourism booking service — it is a structured clinical navigation program built around the specific requirements of patients with complex conditions who need genuine MDT-level care.

8.1 The MedBridge Clinical Navigation Process for MDT Access

8.2 MedBridge's MDT Partner Network: Our Vetting Standards

Our institutional vetting process for MDT-capable partners is rigorous, documented, and independently verified. We do not accept institutions' self-reported claims about their MDT processes at face value. Our assessment includes direct review of MDT meeting schedules and attendance records, verification of the participating specialists' credentials and subspecialty training, assessment of the integration of molecular pathology and genomic analysis into routine MDT practice, evaluation of the documentation quality of MDT recommendations, and patient outcome data review where available.